A Phase 3 interventional study of AVT03 and Denosumab in Osteoporosis, Postmenopausal, sponsored by Alvotech Swiss AG. Completed at 34 sites in 5 countries. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-05-29.
Sponsored by Alvotech Swiss AG · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a randomized, double-blind, parallel design, repeat dose, 2 arm, multicenter study comparing the efficacy, safety, immunogenicity, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of AVT03 and US-Prolia in postmenopausal women with osteoporosis.
After the screening activities, eligible subjects were randomized to receive either AVT03 60 mg or Prolia® 60 mg, administered as a subcutaneous (s.c.) injection on Day 1 and at Month 6. At Month 12, subjects in AVT03 treatment group will received a third dose of AVT03 60 mg administered s.c. while subjects in Prolia® treatment group will were be re-randomized 1:1 to receive either Prolia 60 mg or AVT03 60 mg administered as a subcutaneous injection.
Afterwards, the subjects will be followed until the End of Study (EoS) Visit.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
This study's enrollment of 532 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Browse Osteoporosis, Postmenopausal studies →Alvotech Swiss AG is the lead sponsor of 20 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
A baseline dual-energy x-ray absorptiometry (DXA) scan with a T score ≤-2.5 and
Female subject is postmenopausal according to 1 of the following criteria:
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AVT03 is the proposed biosimilar for Prolia.
Biological: AVT03
Biological: Denosumab
AVT03 (denosumab) is a recombinant fully human IgG2 monoclonal antibody to RANKL to be administered as a subcutaneous injection. Subjects in this arm received AVT03 60mg administered s.c. on Day 1 and at Month 6. At Month 12, subjects in the AVT03 arm received a third dose of AVT03 60 mg.
Prolia (denosumab) is a recombinant fully human IgG2 monoclonal antibody to RANKL developed to be administered as a subcutaneous injection. Subjects in this arm received 60mg of commercially available US-Prolia, administered s.c on Day 1 and at Month 6. At Month 12, subjects in the Prolia treatment group were re-randomized in a 1:1 ratio to receive either: * AVT03 60 mg administered s.c. on Day365. * Prolia 60 mg administered s.c. on Day365.
Also known as: Prolia
Percent Change From Baseline in LS BMD at Month 12 to Demonstrate Comparable Efficacy of AVT03 and Prolia®.
Percent Change From Baseline in LS BMD at Month 12 to demonstrate comparable efficacy of AVT03 and Prolia®.
Time frame: Baseline to Month 12
To Demonstrate Comparable Profile of AVT03 and Prolia in Terms of Area Under the Percent Change From Baseline in Serum C-telopeptide of Type 1 Collagen (AUEC of %Cfb sCTX-1)
Time frame: Baseline to Month 6
Percent Change From Baseline in LS BMD
Percent change from Baseline in LS BMD at 6 and 18 months
Time frame: Month 6, Month18
Percent Change From Baseline in Hip and Femoral Neck BMD
Percent change from Baseline in hip and femoral neck BMD at Month 6, 12 and 18 months
Time frame: Month 6, Month 12, Month 18
Incidence of New Morphometric Vertebral Fractures
Incidence of new morphometric vertebral fractures at 12 and 18 months
Time frame: Month 12 and 18
Percent Change From Baseline in sCTX-1
Percent change from Baseline in sCTX-1 at 3, 6, 9, 12 and 18 months
Time frame: Month 3, Month 6, Month 9, Month 12 and Month 18
Incidence, Nature and Severity of Adverse Events Including Adverse Drug Reactions
Time frame: Month 18
Frequency and Severity of Injection Site Reactions
Time frame: Month 12
Frequency and Severity of Findings in Routine Safety Parameters
Time frame: Month 18
Frequency and Titer of Anti-drug Antibodies and Frequency of Neutralizing Antibodies Against AVT03 and Prolia
Time frame: Month 18
Serum Trough Concentration of AVT03 and Prolia
Time frame: Month 18
| Milestone | AVT03 | Prolia | Prolia/AVT03 (Month 12 to Month18) |
|---|---|---|---|
| Started | 266 | 266 | 0 |
| Completed | 242 | 244 | 0 |
| Not completed | 24 | 22 | 0 |
| Withdrew: Adverse event | 7 | 2 | 0 |
| Withdrew: Death | 3 | 1 | 0 |
| Withdrew: Withdrawal by subject | 11 | 16 | 0 |
| Withdrew: Protocol violation | 2 | 3 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Milestone | AVT03 | Prolia | Prolia/AVT03 (Month 12 to Month18) |
|---|---|---|---|
| Started | 242 | 122 | 122 |
| Completed | 237 | 120 | 119 |
| Not completed | 5 | 2 | 3 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 2 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 |
| Withdrew: Other reasons | 0 | 0 | 1 |
Percent Change From Baseline in LS BMD at Month 12 to demonstrate comparable efficacy of AVT03 and Prolia®.
| Percent Change From Baseline in LS BMD | AVT03 | Prolia |
|---|---|---|
| Percent Change From Baseline in LS BMD at Month 12 to Demonstrate Comparable Efficacy of AVT03 and Prolia®. | 5.3 ± 0.870 | 5.18 ± 0.872 |
| percentage change from baseline*days | AVT03 | Prolia |
|---|---|---|
| To Demonstrate Comparable Profile of AVT03 and Prolia in Terms of Area Under the Percent Change From Baseline in Serum C-telopeptide of Type 1 Collagen (AUEC of %Cfb sCTX-1) | 2345.55 ± 1.011 | 2342.87 ± 1.011 |
Percent change from Baseline in LS BMD at 6 and 18 months
Results for this outcome have not been posted.
Percent change from Baseline in hip and femoral neck BMD at Month 6, 12 and 18 months
Results for this outcome have not been posted.
Incidence of new morphometric vertebral fractures at 12 and 18 months
Results for this outcome have not been posted.
Percent change from Baseline in sCTX-1 at 3, 6, 9, 12 and 18 months
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over From baseline to Month 18. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AVT03 (Baseline to Month 12) | 3/266 (1.1%) | 9/266 (3.4%) | 178/266 (66.9%) |
| Prolia (Baseline to Month 12) | 1/266 (0.4%) | 10/266 (3.8%) | 178/266 (66.9%) |
| AVT03 (Month 12 to Month18) | 1/242 (0.4%) | 6/242 (2.5%) | 99/242 (40.9%) |
| Prolia/AVT03 (Month 12 to Month18) | 0/122 (0%) | 3/122 (2.5%) | 39/122 (32%) |
| Prolia/Prolia (Month 12 to Month18) | 0/122 (0%) | 2/122 (1.6%) | 39/122 (32%) |
| Event | AVT03 (Baseline to Month 12) | Prolia (Baseline to Month 12) | AVT03 (Month 12 to Month18) | Prolia/AVT03 (Month 12 to Month18) | Prolia/Prolia (Month 12 to Month18) |
|---|---|---|---|---|---|
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/266 | 0/266 | 0/242 | 1/122 | 0/122 |
| Cardiac failure congestiveCardiac disorders | 0/266 | 0/266 | 0/242 | 0/122 | 1/122 |
| Deafness bilateralEar and labyrinth disorders | 0/266 | 0/266 | 0/242 | 1/122 | 0/122 |
| CholecystitisHepatobiliary disorders | 0/266 | 0/266 | 0/242 | 0/122 | 1/122 |
| AppendicitisInfections and infestations | 0/266 | 1/266 | 0/242 | 0/122 | 1/122 |
| Femur fractureInjury, poisoning and procedural complications | 0/266 | 0/266 | 0/242 | 1/122 | 0/122 |
| PancytopeniaBlood and lymphatic system disorders | 0/266 | 0/266 | 1/242 | 0/122 | 0/122 |
| DiplopiaEye disorders | 0/266 | 0/266 | 1/242 | 0/122 | 0/122 |
| Intestinal obstructionGastrointestinal disorders | 0/266 | 0/266 | 1/242 | 0/122 | 0/122 |
| Sudden deathGeneral disorders | 0/266 | 1/266 | 1/242 | 0/122 | 0/122 |
| Event | AVT03 (Baseline to Month 12) | Prolia (Baseline to Month 12) | AVT03 (Month 12 to Month18) | Prolia/AVT03 (Month 12 to Month18) | Prolia/Prolia (Month 12 to Month18) |
|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 32/266 | 36/266 | 7/242 | 1/122 | 8/122 |
| HypocalcaemiaMetabolism and nutrition disorders | 28/266 | 23/266 | 5/242 | 1/122 | 3/122 |
| NasopharyngitisInfections and infestations | 23/266 | 20/266 | 9/242 | 3/122 | 2/122 |
| Activated partial thromboplastin time prolongedInvestigations | 13/266 | 15/266 | 8/242 | 3/122 | 6/122 |
| Urinary tract infectionInfections and infestations | 14/266 | 5/266 | 3/242 | 3/122 | 3/122 |
| Adjusted calcium decreasedInvestigations | 14/266 | 6/266 | 8/242 | 4/122 | 0/122 |
| HypertensionVascular disorders | 12/266 | 8/266 | 2/242 | 0/122 | 2/122 |
| InfluenzaInfections and infestations | 8/266 | 11/266 | 0/242 | 1/122 | 0/122 |
| Injection site reactionGeneral disorders | 10/266 | 8/266 | 1/242 | 1/122 | 1/122 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 10/266 | 9/266 | 3/242 | 0/122 | 0/122 |
| Age, Continuous(years) | AVT03 | Prolia | Total |
|---|---|---|---|
| Mean | 65.2 ± 6.94 | 64.5 ± 7.04 | 64.9 ± 7 |
| Sex: Female, Male(Participants) | AVT03 | Prolia | Total |
|---|---|---|---|
| Female | 266 | 266 | 532 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | AVT03 | Prolia | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 13 | 11 | 24 |
| White | 246 | 249 | 495 |
| More than one race | 2 | 0 | 2 |
| Unknown or Not Reported | 5 | 6 | 11 |
| Region of Enrollment(participants) | AVT03 | Prolia | Total |
|---|---|---|---|
| Czechia | 28 | 33 | 61 |
| Poland | 144 | 144 | 288 |
| South Africa | 47 | 41 | 88 |
| Georgia | 33 | 37 | 70 |
| Bulgaria | 14 | 11 | 25 |
| BMI at screening(kg/m^2) | AVT03 | Prolia | Total |
|---|---|---|---|
| Mean | 25.12 ± 3.547 | 25.2 ± 3.605 | 25.16 ± 3.573 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2022 to primary completion in May 2024, 20 months.
Results were first posted in May 2025, 1 year after primary completion.
Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 20 months is below that.
Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AVT03
Osteoporosis, Postmenopausal →
Alvotech Swiss AG